Key Points

• Dupixent (dupilumab), a widely used eczema and asthma medication, has been linked in published studies to an increased risk of Cutaneous T-Cell Lymphoma (CTCL), a rare cancer of the skin. 
• Lawsuits allege that the makers of Dupixent failed to warn patients and doctors about the cancer risk, and more families continue to come forward. 
• People who used Dupixent and were later diagnosed with CTCL, or whose cancer worsened while on the drug, may qualify to file a lawsuit and seek compensation. 

Why It Matters

Millions of people have used Dupixent to manage eczema and asthma, trusting that it was safe. A growing body of research now suggests the drug may raise the risk of a serious blood cancer that affects the skin. Because CTCL can be mistaken for a common skin condition, some patients learn the truth only after the disease has advanced. For patients and families facing this diagnosis, understanding the link is the first step toward protecting their health and their legal rights. 

Dupixent and Your Right to Seek Compensation

If you or a loved one used Dupixent and were diagnosed with Cutaneous T-Cell Lymphoma, you may be eligible to file a lawsuit and receive compensation. Lawsuits across the U.S. have been filed against the makers of Dupixent alleging that they failed to warn patients and their doctors about the cancer risk linked to the drug. 

Our law firm, Hissey Mulderig & Friend, is currently investigating claims involving cases of Cutaneous T-Cell Lymphoma linked to Dupixent. 

Find out whether you may qualify to file a Dupixent lawsuit or start your claim today by contacting our offices toll-free at 1-866-806-8117, or by sending us your information using the free case evaluation form on this page to get started. 

What Is Cutaneous T-Cell Lymphoma (CTCL)?

Cutaneous T-Cell Lymphoma is a rare type of non-Hodgkin lymphoma, a cancer that begins in white blood cells called T-cells. In CTCL, these cancerous cells build up in the skin. The disease can be hard to recognize because its early symptoms often look like common skin conditions such as eczema or a rash. 

Two forms of CTCL have been connected to Dupixent use: 

• Mycosis fungoides, the most common form, which causes patches, plaques, or bumps on the skin. 
• Sezary syndrome, a rarer and more aggressive form that affects both the skin and the blood. 

Common symptoms of CTCL include red rashes or scaly patches, intense itching, swollen lymph nodes, fatigue, and unexplained weight loss.  

Because these signs can mimic eczema, some patients may not learn they have cancer until the disease has progressed. A correct diagnosis usually requires a skin biopsy and follow-up testing by a specialist. 

How Is Dupixent Linked to CTCL?

Dupixent works by changing how the immune system responds to inflammation. Researchers have raised concerns that this same action may allow certain cancers to grow or go unnoticed. There is also worry that the drug can ease eczema-like symptoms that are actually early signs of lymphoma, which can mask the cancer and delay diagnosis. 

According to a 2024 study published in the Journal of the American Academy of Dermatology, patients treated with Dupixent were more than three times as likely to develop CTCL as people who never used the drug.  

Another study, published the following year in the European Respiratory Journal, found that asthma patients taking Dupixent faced nearly four times the risk of lymphoma compared with those on other treatments. According to the study, this risk increased the longer that Dupixent was being used. 

The U.S. Food and Drug Administration (FDA) has received nearly 300 FAERS reports of lymphoma among Dupixent users, including roughly 138 of cutaneous T-cell lymphoma. The agency is currently reviewing whether an alert about lymphoma should be added to the warning label for Dupixent. 

What the Dupixent Lawsuits Claim

The first Dupixent lawsuit was filed in October 2025 on behalf of a woman who died from T-cell lymphoma after being treated with the drug. Since then, more lawsuits have been filed over the alleged link between Dupixent and lymphoma. 

These cases have alleged that Regeneron and Sanofi, the manufacturers of Dupixent, failed to warn patients and doctors about the risk of developing CTCL. The lawsuits have also alleged that Dupixent may cause lymphoma to appear or grow more aggressively, and that because CTCL can look like eczema, some patients kept using the drug while their cancer went undiagnosed, which may have allowed the disease to spread. 

The Dupixent litigation is still in its early stages, but it is growing quickly. After the first case was filed in late 2025, additional lawsuits have been brought in federal courts around the country by patients and families who say the drug caused or worsened their cancer. 

Legal observers expect the number of claims to keep rising as more of the hundreds of thousands of Dupixent users learn about the potential link between this drug and T-cell lymphoma.  

Do You Qualify to File a Dupixent Lawsuit?

Patients who used Dupixent to treat eczema, asthma, or another condition and were later diagnosed with Cutaneous T-Cell Lymphoma, including mycosis fungoides or Sezary syndrome, may be eligible to joins the lawsuits against Dupixent.  

Patients whose lymphoma became worse after they started the drug, or who died from the disease, may also be eligible to take legal action. 

Dupixent users who qualify for a lawsuit may be able to recover compensation for medical bills, lost wages, pain and suffering, and, in cases involving a death, wrongful death damages.  

Time limits called statutes of limitations apply to these claims, so it is important to talk with a lawyer as soon as possible to preserve your right to file a claim.  

Every case is different, so the only way to know your legal rights and find out whether you may be eligible to file a lawsuit is to have an experienced attorney review your history and help explain your legal options. 

Talk to Hissey, Mulderig & Friend Today

If you or a loved one was diagnosed with Cutaneous T-Cell Lymphoma after using Dupixent, you may be eligible to join the lawsuits filed against the makers of this drug.  

The attorneys at Hissey, Mulderig & Friend have spent decades holding drug companies accountable for dangerous products. Our firm works on a contingency basis, meaning that you will never have to pay legal fees unless you receive compensation from your claim. 

Find out whether you qualify to file a lawsuit, schedule a free attorney consultation, or start your claim today by contacting Hissey Mulderig & Friend toll-free at 1-866-806-8117, or by filling out our free contact form, located at the top of this page.